|Bid||162.12 x 200|
|Ask||163.40 x 300|
|Day's Range||161.72 - 167.85|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||225.90|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 1Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues close to $186 million, of which $102 million came from the US market.
Gilead Sciences, Inc.'s revenue is estimated to decline by just over 18% when it reports its Q2 results.
ertex Pharmaceuticals’ Orkambi also secured U.S. Food and Drug Administration’s (or FDA) approval for CF patients in the age group of six to 11 years in September 2016.